Related references
Note: Only part of the references are listed.Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study
Salvatore Del Prete et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Enhanced Expression of Vascular Endothelial Growth Factor-A in Ground Glass Hepatocytes and Its Implication in Hepatitis B Virus Hepatocarcinogenesis
Jui-Chu Yang et al.
HEPATOLOGY (2009)
Vibrio vulnificus-induced Cell Death of Human Mononuclear Cells Requires ROS-dependent Activation of p38 and ERK 1/2 MAPKs
Woo Hyang Kim et al.
IMMUNOLOGICAL INVESTIGATIONS (2009)
Angiogenesis in liver disease
Mercedes Fernandez et al.
JOURNAL OF HEPATOLOGY (2009)
Management of advanced hepatocellular carcinoma in the era of targeted therapy
Thomas Yau et al.
LIVER INTERNATIONAL (2009)
Dual-specificity phosphatase 1 ubiquitination in extracellular signal-regulated kinase-mediated control of growth in human hepatocellular carcinoma
Diego F. Calvisi et al.
CANCER RESEARCH (2008)
Mechanisms of action and resistance of somatostatin analogues for the treatment of hepatocellular carcinoma: A message not well taken
Dimitrios N. Samonakis et al.
DIGESTIVE DISEASES AND SCIENCES (2008)
Molecular mechanisms for discrete nitric oxide levels in cancer
Lisa A. Ridnour et al.
NITRIC OXIDE-BIOLOGY AND CHEMISTRY (2008)
Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma
Diego F. Calvisi et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Manganese superoxide dismutase activity and incidence of hepatocellular carcinoma in patients with Child-Pugh class A liver cirrhosis: a 7-year follow-up study
Caterina Clemente et al.
LIVER INTERNATIONAL (2007)
Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: Randomized placebo-controlled trial
D. Dimitroulopoulos et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2007)
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
P. J. Roberts et al.
ONCOGENE (2007)
Inflammation and IGF-I activate the Akt pathway in breast cancer
Robyn L. Prueitt et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Continuing declines in cancer mortality in the European Union
F. Levi et al.
ANNALS OF ONCOLOGY (2007)
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
Li Liu et al.
CANCER RESEARCH (2006)
Treatment of hepatocellular carcinoma
Alejandro Forner et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2006)
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
Ghassan K. Abou-Alfa et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Protein kinase C α trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2
Wu Wen-Sheng
CANCER LETTERS (2006)
Targeting Raf-kinase: molecular rationales and translational issues
M. Caraglia et al.
ANNALS OF ONCOLOGY (2006)
Whole blood fixation and permeabilization protocol with red blood cell lysis for flow cytometry of intracellular phosphorylated epitopes in leukocyte subpopulations
S Chow et al.
CYTOMETRY PART A (2005)
Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas
M Bläker et al.
JOURNAL OF HEPATOLOGY (2004)
Primary liver cancer:: Worldwide incidence and trends
FX Bosch et al.
GASTROENTEROLOGY (2004)
Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma
YH Hwang et al.
HEPATOLOGY RESEARCH (2004)
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival
JM Llovet et al.
HEPATOLOGY (2003)
Targeting ras signalling pathways in cancer therapy
J Downward
NATURE REVIEWS CANCER (2003)
Molecular pathogenesis of human hepatocellular carcinoma
SS Thorgeirsson et al.
NATURE GENETICS (2002)
The rise and fall in primary liver cancer mortality in Italy
C La Vecchia et al.
DIGESTIVE AND LIVER DISEASE (2002)
International trends and patterns of primary liver cancer
KA McGlynn et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Recruitment of dendritic cells and enhanced antigen-specific immune reactivity in cancer patients treated with hr-GM-CSF (Molgramostim) and hr-IL-2: results from a phase Ib clinical trial
P Correale et al.
EUROPEAN JOURNAL OF CANCER (2001)
Share Paper
